ClinicalTrials.gg
CompletedNCT05583955Updated Feb 20, 2026Results posted

A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus)

A Phase 2 interventional study of NOE-105 and Placebo in Childhood-Onset Fluency Disorder, sponsored by Noema Pharma AG. Completed at 9 sites in 2 countries. Open to male participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Noema Pharma AG · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This study is designed to evaluate the effectiveness of NOE-105 on speech fluency without the known antipsychotic-induced side effects of commonly used treatments for childhood onset fluency disorder (COFD).

Read the detailed description

NOE-105 is an investigational selective PDE10A inhibitor with a potential therapeutic effect for the treatment of COFD. In this study adult male patients may be randomized to a double-blind, placebo-controlled, parallel group treatment with NOE-105 or placebo once daily. The study is designed to find the maximum tolerated dose of NOE-105 and thereafter, to maintain the participants at this dose until they have completed a total of 10 weeks treatment period. Following up to 10 weeks of treatment, participants will visit the study site for a follow-up visit within 28 (± 7) days of the date of the last dose of study treatment.

02

Conditions studied

  • Childhood-Onset Fluency Disorder
03

In context

Lead sponsor

Noema Pharma AG is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must be 18 to 55 years of age inclusive, at the time of signing the .
  2. Patients who satisfy criteria for childhood onset fluency disorder and are suitable for pharmacotherapy.
  3. Have a history of stuttering for more than or equal to ≥ 2 years with onset consistent to developmental in nature before age 8 years.
  4. Patient reported global stuttering experience as "moderate" at screening and baseline.
  5. Patients must discontinue all medications used to treat stuttering for at least 14 days prior to receiving study treatment. With the exception of antipsychotic therapies (see exclusion criterion #11), other psychotropic drugs will be allowed provided they have been stable for at least 14 days prior to receiving study treatment and are expected to remain stable for the duration of the study.
  6. within the range 19 to 35 kg/m2 (inclusive).
  7. Male use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    Male patients must use a condom during the treatment period and until the end of relevant systemic exposure in the male participant, plus a further 90-day period. In addition, for a non-pregnant partner.

  8. Capable of giving signed informed consent
  9. Able to read and write in English

Exclusion criteria

Exclusion Criteria:

  1. Stuttering is related to a known neurological cause eg, stroke, etc.
  2. Low IQ in the opinion of the investigator.
  3. Patients with uncontrolled seizure disorders.
  4. A history of severe traumatic brain injury or stroke.
  5. Patients who are, in the investigator's opinion, at imminent risk of suicide.
  6. Known to have tested positive for .
  7. Known diagnosis of substance abuse or dependence.
  8. Unstable medical illness or abnormalities on screening tests/exams.
  9. Any unstable medical conditions or are currently ill (eg, congenital heart disease, arrhythmia or cancer), which, in the investigator's judgment, will put them at a risk of major adverse event during this trial, are expected to progress during the study, or will interfere with safety and efficacy assessments.
  10. Initiation of new behavioral therapies for stuttering within 10 weeks prior to baseline.
  11. Use of antipsychotic drug therapy within 14 days prior to receiving treatment until the EoT visit.
  12. Participation in another clinical study with an IP administered in the last 30 days.
  13. Participants with a known to NOE-105 or any of the of the product.
  14. Patient must not intend to use cannabinoids, cocaine, or nonprescribed opiates.
  15. Involvement in the planning and/or conduct of the study (applies to both Noema staff and/or staff at the study site).
  16. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
  17. Previous randomization in the present study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Active

    Escalating doses of NOE-105 capsules

    Drug: NOE-105

  • Placebo comparator
    Placebo

    Escalating doses of matching placebo

    Drug: Placebo

Interventions

  • DrugNOE-105

    Escalating dose levels of NOE-105 will be given and maximum tolerated dose will be maintained

    Also known as: Escalating dose levels of NOE-105

  • DrugPlacebo

    Escalating dose levels of matching Placebo will be given

    Also known as: Placebo to match

06

What researchers measure

Primary outcomes

  1. Change From Baseline to End of 6 Weeks in Total MLGSSS

    MLGSSS refers to Maguire-Leal-Garibaldi Self-rated Stuttering Scale. The scale includes ten questions that are assessed on a 0 to 10 scale with 0 being no impact and 10 being highest impact. The total score ranges from 0 to 100 with the higher the score the worse the stuttering.

    Time frame: 43 days

Secondary outcomes

  1. Change From Baseline in Sheehan Disability Scale

    The Sheehan Disability Scale (SDS) is a brief, self-report tool that assesses disability or functional impairment in the domains of (1) Work/School life, (2) Social life, and (3) Family life/home responsibilities. Each is assessed on a 10 point scale with 0 being no impact, and 10 being highest impact. Each item is rated from 0 (not at all) to 10 (extremely) impairment. Each domain score is added to provide a total score from 0-30 total score with 0 (no impairment) and 30 is severe impairment. The change from the Baseline assessment have been provided.

    Time frame: Up to 71 days

  2. Change From Baseline to End Point in Clinician-rated Stuttering Severity Instrument-4

    SSI-4 is a validated scale to evaluate speech fluency including frequency, duration, physical concomitants and the naturalness of the speech. The score ranges from 10 (mildest) to 46 (most severe). The results show the change from Baseline in the SSI-4

    Time frame: Up to 71 days

07

Results

Posted Feb 3, 2026

Participant flow

Participant flow — Overall Study
MilestoneActivePlacebo
Started3431
Full analysis set3329
Completed1926
Not completed155

Outcome measures

PrimaryChange From Baseline to End of 6 Weeks in Total MLGSSS

MLGSSS refers to Maguire-Leal-Garibaldi Self-rated Stuttering Scale. The scale includes ten questions that are assessed on a 0 to 10 scale with 0 being no impact and 10 being highest impact. The total score ranges from 0 to 100 with the higher the score the worse the stuttering.

Time frame:
43 days
Reported as:
Mean · Score on a scale
Change From Baseline to End of 6 Weeks in Total MLGSSS
Score on a scaleActivePlacebo
Change From Baseline to End of 6 Weeks in Total MLGSSS-7.0 ± 13.32-5.5 ± 6.72
SecondaryChange From Baseline in Sheehan Disability Scale

The Sheehan Disability Scale (SDS) is a brief, self-report tool that assesses disability or functional impairment in the domains of (1) Work/School life, (2) Social life, and (3) Family life/home responsibilities. Each is assessed on a 10 point scale with 0 being no impact, and 10 being highest impact. Each item is rated from 0 (not at all) to 10 (extremely) impairment. Each domain score is added to provide a total score from 0-30 total score with 0 (no impairment) and 30 is severe impairment. The change from the Baseline assessment have been provided.

Time frame:
Up to 71 days
Reported as:
Mean · score on a scale
Change From Baseline in Sheehan Disability Scale
score on a scaleActivePlacebo
Change From Baseline in Sheehan Disability Scale-0.6 ± 8.23-1.3 ± 5.82
SecondaryChange From Baseline to End Point in Clinician-rated Stuttering Severity Instrument-4

SSI-4 is a validated scale to evaluate speech fluency including frequency, duration, physical concomitants and the naturalness of the speech. The score ranges from 10 (mildest) to 46 (most severe). The results show the change from Baseline in the SSI-4

Time frame:
Up to 71 days
Reported as:
Mean · units on a scale
Change From Baseline to End Point in Clinician-rated Stuttering Severity Instrument-4
units on a scaleActivePlacebo
Change From Baseline to End Point in Clinician-rated Stuttering Severity Instrument-4-3.0 ± 6.5-2.7 ± 4.78
Post-hocChange in MLGSSS From Baseline in More Severe Population

MLGSSS refers to Maguire-Leal-Garibaldi Self-rated Stuttering Scale. The scale includes ten questions that are assessed on a 0 to 10 scale with 0 being no impact and 10 being highest impact. The total score ranges from 0 to 100 with the higher the score the worse the stuttering. Analysis of a subset of participant with a Baseline MLGSSS of \> 24, in other words this analysis excludes those with mild stuttering as measured by MLGSSS. See the description for the first outcome measure for a description of the scale. The results show the change from baseline.

Time frame:
Up to 71 days
Reported as:
Mean · score on a scale
Change in MLGSSS From Baseline in More Severe Population
score on a scaleActivePlacebo
Change in MLGSSS From Baseline in More Severe Population-14.8 ± 12.54-9.1 ± 8.81

Adverse events

Collected over Adverse events were collected for the duration of the trial (71 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active0/34 (0%)0/34 (0%)23/34 (67.6%)
Placebo0/31 (0%)0/31 (0%)13/31 (41.9%)
Most frequent other events
Showing 10 of 31
Most frequent other events
EventActivePlacebo
SedationNervous system disorders8/341/31
NasopharyngitisInfections and infestations0/344/31
DystoniaNervous system disorders3/340/31
SomnolenceNervous system disorders3/340/31
AkathisiaNervous system disorders3/340/31
RestlessnessPsychiatric disorders3/340/31
Upper respiratory tract infectionInfections and infestations1/342/31
Muscle twitchingMusculoskeletal and connective tissue disorders0/342/31
TremorNervous system disorders2/341/31
BradykinesiaNervous system disorders2/340/31

Baseline characteristics

Age, Continuous
Age, Continuous(years)ActivePlaceboTotal
Mean31.1 ± 10.0934.3 ± 10.2532.6 ± 10.22
Sex: Female, Male
Sex: Female, Male(Participants)ActivePlaceboTotal
Female000
Male343165
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ActivePlaceboTotal
American Indian or Alaska Native000
Asian516
Native Hawaiian or Other Pacific Islander011
Black or African American10919
White171532
More than one race000
Unknown or Not Reported257
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ActivePlaceboTotal
Hispanic or Latino336
Not Hispanic or Latino312758
Unknown or Not Reported011
Maguire-Leal-Garibaldi Self-rated Stuttering Scale
Maguire-Leal-Garibaldi Self-rated Stuttering Scale(score on a scale)ActivePlaceboTotal
Mean32.1 ± 14.2333.3 ± 11.1632.7 ± 12.86
08

Study locations

9 sites
  • Noema Investigator site
    Bellflower, California 90706, United States
  • Noema Investigator site
    Jacksonville, Florida 32256, United States
  • Noema Investigator site
    Orlando, Florida 32801, United States
  • Noema Investigator site
    Overland Park, Kansas 66210, United States
  • Noema Investigator site
    Berlin, New Jersey 08009, United States
  • Noema Investigator site
    Memphis, Tennessee 38119, United States
  • Noema Investigator site
    Brookvale, New South Wales 2100, Australia
  • Noema Investigator site
    Miranda, New South Wales 2228, Australia
  • Noema Investigator site
    Sydney, New South Wales 2109, Australia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Oct 2023, 14 months.

Results were first posted in Feb 2026, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2022
First posted
Oct 18, 2022
StartActual
Jul 25, 2022
Primary completionActual
Oct 20, 2023
CompletionActual
Nov 24, 2023
Results first posted
Feb 3, 2026
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05583955
Lead sponsor
Noema Pharma AG
Responsible party
Sponsor
First posted
Oct 18, 2022
Start date
Jul 25, 2022
Primary completion
Oct 20, 2023
Completion
Nov 24, 2023
Results posted
Feb 3, 2026
Last update
Feb 20, 2026

Study contacts

Gerald A Maguire, M.D.
principal investigator · Clinical Innovations, Inc. dba CITrials (a CenExel company)

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion